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Abstract. It has been demonstrated that connexin 43 (Cx43) 
and microRNAs have significant roles in glioma. Cyclic 
adenosine monophosphate (cAMP) is suggested to be a 
regulator of connexins and microRNAs. However, it remains 
elusive whether cAMP and exchange protein directly activated 
by cAMP (Epac2), have a regulatory effect on Cx43 and 
microRNA-451 (miR-451) in astrocytoma cells. We treated 
1321N1 astrocytoma cells with a selective β2 adrenergic agonist 
and a selective Epac activator with and without adenyl cyclase 
and protein kinase A inhibition. Cx43 and miR-451 expression 
were measured. Next, we evaluated the effect of miR-451 over-
expression on Cx43 expression. Cell proliferation was measured 
using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay. The results demonstrated that cAMP-
Epac2 increased Cx43 and miR-451 expression. However, the 
alteration of miR-451 expression required a higher dose of 
drugs. Overexpression of miR-451 had no significant effect 
on Cx43 expression. The MTT assay showed that cAMP-Epac 
stimulation and miR-451 overexpression had a synergic inhibi-
tory effect on cell proliferation. These findings may expand our 
understanding of the molecular biology of glioma and provide 
new potential therapeutic targets.
Introduction
Gliomas and astrocytomas are brain tumors that are associ-
ated with a high mortality rate and current treatments have not 
significantly improved patient survival (1). The gap junction, 
which is required for maintaining cell growth, has been reported 
to be absent in gliomas and astrocytomas. The gap junction is 
made of connexin proteins, which have been proposed to act 
as tumor suppressors (2,3). Connexin 43 (Cx43) is the major 
protein forming gap junction channels in astrocytes and has 
been proposed to have growth inhibitory effects. Expression of 
Cx43 is inversely correlated with the degree of malignancy (3). 
It is accepted that connexins not only act as critical gatekeepers 
of cell proliferation by controlling the intercellular exchange 
of essential growth regulators, but they may also affect cell 
cycling by non-gap junctional intercellular communication (4).
By contrast, the abnormal expression of microRNAs 
(miRNAs) has been linked with several types of cancer, 
including glioma (5). miRNAs are endogenous eukaryotic small, 
non-coding RNAs that negatively regulate gene expression (6). 
The study of the expression profile of miRNA in glioblastoma 
indicated that mir-451 is significantly decreased in glioblastoma 
compared with normal brain tissue (7). Overexpression of 
miR-451 in glioblastoma cells led to the inhibition of glioblas-
toma cell growth, invasive ability and enhanced apoptosis (8).
Another line of evidence indicated that higher grades of 
human brain tumors are associated with lower adenyl cyclase 
activity and/or cellular cAMP concentrations (9). It was 
stated that the β2-adrenergic receptor (β2-AR) is expressed in 
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glioblastomas, as well as in the human-derived 1321N1 astro-
cytoma cell line (10). cAMP and its related compounds inhibit 
the proliferation of tumor cells (11). Furthermore, studies have 
revealed an association between cAMP and Cx43 (12), and 
also between cAMP levels and the expression of miRNA (13). 
By contrast, other studies have demonstrated an association 
between miRNAs and Cx43 expression (14).
Since the data in the Oncomine cancer profiling database 
(http://www.oncomine.org) suggests a significant portion of 
gliomas and astrocytomas express the β2-AR to a greater extent 
than in normal brain tissue, this receptor represents a potential 
therapeutic target for the treatment of these tumors (15). In the 
present study, we analyzed the possible interaction between 
the cAMP-Epac signaling pathway, Cx43 and miR-451 expres-
sion in astrocytoma cells.
Materials and methods
Reagents. All drugs, including a selective β2-AR agonist, 
clenbuterol hydrochloride (C5423), adenylyl cyclase 
inhibitor (SQ 22,536; S153), PKA specific inhibitor (H-89; 
B1427) and Epac-specific activator 8-(4-chlorophenylthio)-2 
-O-methyladenosine-3,5-cyclic monophosphate (8CPT; 
C8988) were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Antibodies including mouse monoclonal to cx43/
GJA1 (ab79010), rabbit polyclonal to Epac2 (ab21238), mouse 
monoclonal to β-actin (ab6276), rabbit polyclonal secondary 
antibody to mouse IgG (ab6728) and goat polyclonal secondary 
antibody to rabbit IgG (ab6721) were purchased from Abcam 
(Cambridge, MA, USA).
Cell culture. The human astrocytoma cell line 1321N1 was 
obtained from the National Cell bank of Iran, (Tehran, Iran) 
and maintained in DMEM containing 10% FBS supplemented 
with 100 unit/ml penicillin and 50 mg/ml streptomycin in a 
humidified atmosphere at 5% CO2 and 37˚C. Cells were plated 
for RNA extraction and western blot analysis in six-well plates. 
Prior to drug exposure in all experiments, the medium of 
70-80% confluent cells was changed with DMEM containing 
1% FBS. 
Cell proliferation assay. Cell proliferation was quantified 
using an MTT assay (Sigma-Aldrich). Mir-451 transfected 
and untransfected cells were seeded in 96-well plates with a 
density of 0.5x104 cells/well containing DMEM. The attached 
cells were incubated for another 24 and 48 h with of 10 µg/ml 
ß2 agonist; 10 µg/ml ß2 agonist + 20 µg/ml AC inhibitor; and 
20 µg/ml Epac activator, with DMEM as a control. Next, cells 
were incubated with 5 mg/ml of MTT solution at 37˚C for 3 h. 
We dissolved the formazan crystals in DMSO. The optical 
density of each well was measured using a microplate reader 
(BioTek Instruments, Inc., Winooski, VT, USA) measuring at a 
wavelength of 570 nm with background subtraction at 630 nm. 
The experiments were performed and repeated 3 times. We 
determined each treatment for mean values ± SE.
Real-time RT-PCR. Total RNA, isolated with QIAzol (Qiagen, 
Hilden, Germany) according to the manufacturer's instruc-
tions, was used for complementary DNA (cDNA) synthesis by 
reverse transcriptase (Vivantis, Oceanside, CA, USA; cat no: 
RTPL12). Specific primers for human Cx43 (forward: 5'-GAT 
GAG GAA GGA AGA GAA G-3', reverse: 5'-CGC TAG CTT 
GCT TGT TGT AA-3') and β-actin (forward: 5'-GCA AGA 
GAG GTA TCC TGA CC-3', reverse: 5'-CCC TCG TAG ATG 
GGC ACA GT-3') were used for this experiment using Takara 
SYBR Premix Ex Taq Master (Takara Bio, Inc., Shiga, Japan). 
Gene expression levels were quantified by Rotor-Gene 6000 
(Corbett, Concorde, NSW, Australia). The relative expression 
ratio of Cx43 and β-actin were calculated using the relative 
expression software tool (REST).
Immunoblotting assay. Total cell lysates were prepared 
following harvesting cells in ice-cold PBS and homogeniza-
tion in cold lysis buffer (RIPA buffer). Protease inhibitor 
cocktail (S8820; Sigma-Aldrich) was added to the lysis buffer. 
The lysate was centrifuged at 13,680 x g for 10 min and the 
supernatant was transferred to a new tube. Protein content 
was measured using the bicinchoninic acid assay (BCA 
protein kit; Pierce Biotechnology, Inc., Rockford, IL, USA). 
An equal amount of protein (25 µg) per well was loaded to 
12.5% standard SDS-PAGE, then by using a wet system 
(Bio-Rad, Hercules, CA, USA), the proteins and page ruler 
were transferred to PVDF membranes. Membranes were 
blocked in 2% skimmed milk in TBST 20 (Tris-buffered 
saline (TBS)/Tween-20; 0.5%) for 2 h at room temperature. 
Membranes were incubated overnight at 4˚C with primary 
antibodies against cx43 and Epac2 diluted in TBST (1:1000; 
0.5%). Membranes were washed three times with TBST 20 
and subsequently incubated for 1 h at room temperature with 
the following corresponding HRP-conjugated secondary 
antibodies: rabbit polyclonal secondary antibody to mouse 
IgG and goat polyclonal secondary antibody to rabbit IgG. 
Following three washes with TBST 20 (0.5%), detection was 
performed by applying Pierce ECL Plus Western Blotting 
Substrate (#32134), which produced chemiluminescence from 
the membrane for manual X-ray film development. Levels of 
the analyzed proteins were normalized to β-actin levels.
Virus packaging, concentration and transduction of 1321N1 
cells. For virus packaging of PB_miR-451 (contained green 
fluorescent protein (GFP) and puromycin resistance genes), we 
used a human embryonic kidney 293T cell line (HEK 293T). 
These cells were maintained in DMEM containing 10% FBS 
supplemented with 100 unit/ml penicillin and 50 mg/ml 
streptomycin in a humidified atmosphere at 5% CO2 and 37˚C. 
Cells were co-transfected with psPAX2 plasmid containing 
gag/pol packaging genes, pMDG plasmid containing VSV-G 
and PB_miR-451 (as well as an empty vector) using the 
calcium-phosphate method. Following 24 h of transfection, 
GFP expression was assessed using an inverted fluorescence 
microscope (TE2000; Nikon, Tokyo, Japan). The medium 
containing the produced viruses were collected 24, 48 and 72 h 
following transfection and kept at 4˚C followed by concentra-
tion processing, including centrifuging at 21,000 rpm or 
40,000 g at 4˚C for 2.5 h. The concentrated supernatants were 
used to infect 1321N1 human astrocytoma cells. 
Puromycin treatment and total RNA extraction. Following 
24 h of transduction, transducted cells were treated with 
puromycin (2 µg/ml) and treatment was continued for 3 days. 
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Cells in the negative control groups were also treated with 
puromycin and as expected died after 48 h. The experimental 
group (that was transfected with PB_miR-451) was resistant 
to puromycin and survived the antibiotic selection. Total RNA 
(containing miRNAs) was collected following 72 h puromycin 
treatment using QIAzol Lysis Reagent (Qiagen, Valencia, 
USA). An RNA pellet was dissolved in 20 µl distilled water 
and maintained in -70˚C until further use.
miRNA expression verification. To assess the constructs' 
functionality, overexpression of miR-451 was evaluated by 
RT-PCR in transducted 1321N1 cells. Following 72 h, trans-
ducted cells were harvested for miRNA extraction by Qiazol 
reagent (Qiagen). The extracted microRNAs were subjected 
to cDNA synthesis by Stratagene (La Jolla, CA, USA) real-
time RT-PCR kit according to the manufacturer's instructions. 
Briefly, following poly-adenylation of total RNAs, the cDNA 
was synthesized by an adaptor primer provided by Stratagene. 
The relative quantification of miRNAs in comparison to control 
cells was assayed by real-time RT-PCR with Stratagene SYBR 
green master mix (Stratagene), according to the manufacturer's 
instructions in a Rotor-Gene 6000 system (Corbett, Concorde, 
NSW, Australia; n=3). The relative expression ratio of miRNA 
in 1321N1 cells under control conditions and following 24 h 
of treatment with our drugs or overexpression was normalized 
relative to a U6 endogenous control and was then calculated 
using REST. Specific primers for human miR-451 and U6 
were: miR-451 sense: 5'-GGA AGA TCT TGA CAA GGA 
GGA CAG GAG AG-3', miR-451 reverse: 5'-CCC AAG CTT 
GCC TTG TTT GAG CTG GAG TC-3', U6 sense: 5'-CTC 
GCT TCG GCA GCA CA-3', U6 reverse: 5'-AAC GCT TCA 
CGA ATT TGC GT-3'.
Statistical analysis. The obtained data were analyzed using 
the Student's t-test. P<0.05 was considered to indicate a statisti-
cally significant difference (indicated with an asterisk *). Each 
experiment was repeated independently at least three times.
Results
Epac2 expression in 1321N1 astrocytoma cells. Previous 
studies demonstrated the presence of Epac2 in the developing 
and mature brain (16). To determine the putative presence of 
Epac2 in the 1321N1 astrocytoma cell line, we performed a 
western blot analysis to detect endogenous Epac2 and to 
test the effect of the specific β2-AR agonist and 8CPT on 
its expression in astrocytoma cells. As depicted in Fig. 1, we 
found that these cells express the Epac2 protein endogenously. 
Protein bands were detected at a molecular weight of 126 kDa 
for Epac2. The selective β2-AR agonist and Epac activator did 
not significantly increase Epac2 expression.
Effect of β2-AR stimulation and the Epac signaling pathway 
on Cx43 expression. Next, we tested the specificity of cAMP 
signaling on Cx43 expression in astrocytoma cells. Following 
24 h treatment of cells with our drugs, selective β2-AR 
stimulation with clenbuterol hydrochloride (10 µg/ml) led to 
an increase in Cx43 protein level (Fig. 2). This effect was not 
dose dependent (data not shown). 1321N1 cells were pretreated 
with adenyl cyclase (AC) inhibitor, SQ 22,536 (20 µg/ml) and 
H-89 dihydrochloride (10 µg/ml), as a selective PKA inhibitor, 
for 45 min in the presence of clenbuterol. Pretreatment with 
SQ prevented clenbuterol upregulation of Cx43 while cells 
pretreated with H-89 had no effect on Cx43 upregulation, 
suggesting that upregulation of Cx43 observed in the presence 
of clenbuterol does not occur without the PKA pathway. To 
further investigate the possible role of Epac in the upregulation 
of Cx43 we used the selective Epac activator 8-pCPT-2'-O-
Me-cAMP (20 µg/ml). We observed that the protein level of 
Cx43 was increased following 24 h treatment with this drug.
Effect of β2-AR stimulation and the Epac signaling pathway 
on miR-451 expression. Putative regulation of miR-451 by 
our drugs was verified by real time-PCR. Following 24 h 
treatment, a higher dose of β2-AR selective stimulation 
significantly increased miR-451 levels, as 10 and 20 µg/ml 
of clenbuterol had no significant effect on miR-451 expres-
sion. The minimum dose of clenbuterol for the modulation of 
Figure 1. Detection of endogenously expressed Epac2 in 1321N1 cells using 
western blotting. Protein bands of Epac2 were detected at a molecular weight 
of 126 kDa in C, 24 h treated cells with 10 µg/ml β2A and 20 µg/ml 8CPT. 
10% SDS-PAGE was used. This experiment was repeated at least three 
times independently. C, control or untreated; β2A, selective β2 adrenergic 
agonist; 8CPT, 8-(4-chlorophenylthio)-2'-O-methyladenosine-3',5'-cyclic 
monophosphate.
Figure 2. Expression of Cx43 protein in the 1321N1 cells. Cx43 protein 
levels were normalized to that of β-actin protein. Data are expressed as 
the means ± SEM. Each immunoblotting was duplicated to increase the 
reliability of the measurements. Lower panels show representative immu-
noblots of Cx43 (43 kDa). *P<0.05 vs. control group. Cx43, connexin 43; C, 
control or untreated; B, β2 agonist; SB, AC inhibitor + β2 agonist; 8CPT, 
8-(4-chlorophenylthio)-2'-O-methyladenosine-3',5'-cyclic monophosphate; 
B+H89, β2 agonist + PKA inhibitor.
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miR-451 was 40 µg/ml. Adenyl cyclase inhibition prevented 
these changes suggesting adenyl cyclase activation is able to 
increase the miR-451 expression level. To examine whether 
Epac activation is also capable of affecting miR-451 expres-
sion, we treated cells with 8CPT. Selective activation of Epac 
had the same effect of β2-AR stimulation with higher doses, 
as miR-451 increased significantly upon treatment with 8CPT 
(Fig. 3).
Evaluation of miR-451 overexpression in 1321N1 cells. 
For overexpression of miR-451, HEK 293T cells were used 
for virus packaging and these cells were transfected by the 
recombinant vector PB_miR-451. The fluorescent image 
of HEK 293T cells following transfection indicated that the 
majority of the cells were green due to the existence of GFP 
in the vector (Fig. 4A and B). Produced viruses were used for 
transduction. The fluorescent image of 1321N1 cells following 
transduction indicated that the majority of the cells were green 
(Fig. 4C and D). Total RNA was extracted from 1321N1 cells 
and real-time PCR was employed for evaluating the expression 
of miRNA. Results showed that miR-451 was overexpressed in 
comparison with the negative control (Fig. 5).
Effect of miR-451 overexpression on Cx43 and mRNA expres-
sion. Three days following puromycin treatment, the expression 
level of Cx43 mRNA, was evaluated using real-time PCR. 
Real-time PCR results demonstrated non significant altera-
tions in the expression level of the Cx43 gene. Although the 
expression ratio of Cx43 mRNA was 1:2 in the overexpressed 
group compared with the negative control group, this differ-
ence was not significant (Fig. 6). 
Synergic inhibitory effects of cAMP-Epac and miR-451 on cell 
proliferation. The cell proliferation assay revealed that growth 
was inhibited in transfected and treated cells in comparison 
with control cells. Maximum inhibition was observed in trans-
fected cells that were treated with cAMP-Epac related drugs. 
These results demonstrate that miR-451 and the cAMP-Epac 
pathway may have a synergic effect on the inhibition of glioma 
cell growth (Fig. 7).
Discussion
There is widespread agreement that gap junction channels 
formed by the Cx43 protein are likely to play important 
roles (17). Cx43 has a high turnover rate with a half-life of ~1-2 h, 
this condition permits rapid adjustments of cell-cell commu-
nication with transcriptional regulation and degradation (18). 
Modulation of cAMP and its relevant signaling pathway Epac 
are reported to affect the level of Cx43 and its phosphorylation 
in the heart (19,20) and endothelial cells (21). However, the 
molecular nature of β2-AR stimulation and cAMP derivative 
induced Cx43 expression in astrocytoma cells remains unclear. 
We demonstrated that β2-AR stimulation through activation of 
the cAMP cascade upregulates Cx43 expression by increasing 
its mRNA and protein expression in 1321N1 astrocytoma cell 
lines. Investigation of the signaling pathway demonstrated 
that cAMP and its newly described signaling pathway, 
Epac2, mediates β2-AR-enhanced Cx43 expression. Previous 
studies which treated myocardial cells with a non selective 
beta adrenergic agonist stated that β adrenergic receptor and 
cAMP signaling pathway activation led to upregulation of 
Cx43 via activation of PKA and CREB (12,22). One study in 
2009 stated that corticotropin-releasing hormone upregulates 
Cx43 expression partly via the PKA-CREB signaling pathway 
in cultured astrocytes (23). Since the connexin content of 
tumors decreases (2), the upregulation of connexins may 
be of therapeutic value (3). We hypothesized that selective 
stimulation of β2-AR and the cAMP-Epac signaling pathway 
results in Cx43 upregulation in astrocytoma cells. To assess 
this hypothesis, we evaluated the protein level of Cx43 in 
1321N1 cells following our pharmacological interventions on 
cultured cells. Our results demonstrated that 24 h treatment 
with a β2-AR selective agonist increased the protein level of 
Cx43 and this effect was blocked by adenyl cyclase inhibitor, 
Figure 3. Logarithm of fold change of miR-451 following 24 h treatment 
of cells with 10 (B1), 20 (B2) and 40 µg/ml of clenbuterol (B3), 10 µg/ml 
of clenbuterol + 20 µg/ml of adenyl cyclase inhibitor (SB1), 20 µg/ml of 
clenbuterol + 20 µg/ml of adenyl cyclase inhibitor (SB2) and 8CPT (Epac 
activator). It was observed that the highest dose of clenbuterol (40 µg/ml) 
and 8CPT is able to upregulate miR-451. Error bars show the S.D. This 
experiment was repeated at least three times independently. *P<0.05, 
compared with untreated controls. 8CPT, 8-(4-chlorophenylthio)-2'-O-
methyladenosine-3',5'-cyclic monophosphate.
Figure 4. Confirmation of transfection and transduction. HEK 293T cells were 
transfected with vector PB-miR-451-eGFP [plasmid containing sequences for 
microRNA 451 and enhanced green flourescent protein reporter gene (eGFP)]
calcium-phosphate method. (A and B) Fluorescent and phase contrast image of 
HEK 293T cells. Efficient transfection of HEK 293T cells was confirmed by 
visualizing GFP expression after 24 h by an inverted fluorescence microscope. 
(C and D) Fluorescent and phase contrast image of 1321N1 cells. 1321N1 cells 
were transfected with the virus product and following puromycin selection, 
cells were visualized by GFP expression. HEK 293T, human embryonic kidney 
cell line 293T; GFP, green fluorescent protein.
  A   B
  C   D
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SQ. To investigate whether upregulation of Cx43 was working 
through the Epac signaling pathway, we inhibited PKA by H89 
in the presence of β2-AR agonist. Selective β2-AR stimulation 
with simultaneous inhibition of the PKA pathway and thereby 
indirect stimulation of the Epac pathway had the same effect as 
selective β2-AR stimulation. Also, selective Epac stimulation 
in our cells increased the total protein level of Cx43. Toll et al 
(2011) demonstrated that selective β2-AR simulation in 1321N1 
cells led to the inhibition of cell proliferation (15). By contrast, 
other studies indicated that connexins may affect the growth of 
normal or tumor cells, however the precise molecular mecha-
nism by which connexins are capable of inducing this effect 
remains to be elucidated. Recent studies have demonstrated 
that connexins, including Cx43 exert important and extensive 
effects on gene expression, particularly those genes linked to 
growth regulation (17). Therefore, increasing Cx43 expression 
in astrocytoma cells may have a beneficial effect in controlling 
their growth and responsiveness to current treatments.
Effect of the cAMP-Epac signaling pathway on the expres-
sion of microRNAs. The profiling of miRNAs in various 
human disorders and their role in the etiology or treatment of 
them caught the attention of researchers (24). miR-451 was 
identified as a tumor suppressor in glioma and it was demon-
strated that overexpression of miR-451 in glioma cells changed 
their biological behavior (8). Thus, we hypothesized that 
stimulation of the cAMP-Epac signaling pathway may alter 
miR-451 expression level in the 1321N1 astrocytoma cell line. 
Our results revealed a dose-dependent association between 
selective β2-AR stimulation and miR-451 expression level. 
While we have not observed any changes with 10 and 20 µg/
ml of clenbuterol, increasing clenbuterol doses to 40 µg/ml, 
upregulates miR-451 expression level. Selective Epac signaling 
pathway stimulation by 8CPT upregulated miR-451 as well. 
Our findings are in line with other studies which demonstrated 
that the cAMP signaling pathway has a regulatory effect on 
miRNA expression (13). Our study focused mainly on the 
cAMP-Epac pathway and we demonstrated that Epac signaling 
is also involved in the alteration of miRNA biogenesis. We used 
astrocytoma cell lines in our study and it appears that other 
glioma cell lines must be studied before an accurate conclusion 
may be acquired. Although studying the regulation of miRNA 
transcription is an emerging field and further study is needed, 
the evidence we have presented suggests a new effect for the 
cAMP-Epac pathway as a regulator of miR-451 at the tran-
scriptional level in astrocytoma cells. However, higher doses of 
the β2-AR agonist are needed in order to alter miR-451 expres-
sion. Administration of the β2-AR agonist and Epac selective 
stimulation is expected to upregulate miR-451 in vivo.
 Functional analyses of the first identified miRNAs 
determined their roles in cell growth and differentiation (25). 
MiR-451 is significantly downregulated in glioma compared 
with normal brain tissue. The overexpression of miR-451 
in glioma cell lines led to decreased proliferation and inva-
sion (8). Based on our previous results, we demonstrated that 
cAMP has a regulatory effect on Cx43 and miR-451, therefore 
we speculate that these two components have an association 
between them. Next, we overexpressed miR-451 in the 1321N1 
astrocytoma cell line and, following that, Cx43 expression 
level was evaluated. Our results demonstrated that overexpres-
sion of miR-451 had no effect on Cx43 mRNA expression and 
protein level. It seems that the effects of miR-451 and Cx43 
in the progression and/or controlling of tumors were applied 
independently. However, further investigation is required in 
order to elucidate the combinational effect of these biological 
components in patho-physiological processes. For example, 
simultaneous overexpression of miR-451 and Cx43 in astrocy-
toma cells may uncover their cooperative effect.
Figure 5. Expression ratio of miR-451 following transduction of 1321N1 cells. 
It was observed that miR-451 was upregulated 3 days following puromycin 
treatment compared with a control. Error bars show the S.D. This experi-
ment was repeated at least three times independently. *P<0.01 compared with 
untreated controls. C, negative control; Over, transducted 1321N1 cells.
Figure 6. Expression ratio of Cx43 mRNA in 1321N1 cells following over-
expression of miR-451. It was observed that following 3 days of puromycin 
treatment, mRNA of Cx43 in transducted cells increased, however not signifi-
cantly compared with control cells. Error bars show the S.D. This experiment 
was repeated at least three times independently. Cx43, connexin 43; C, nega-
tive control; Over, transducted 1321N1 cells. 
Figure 7. Synergic effects of cAMP-Epac signaling stimulation and over-
expression of miR-451 on cell proliferation. MTT assay in C, 24 and 48 h 
treated cells with B2A, B2A+SQ, 8CPT, miR-451 transfected, transfected 
cells treated with B2A, B2A+SQ and 8CPT. Error bars show the S.D., n=3. 
*P<0.05, significantly different from control 24 h; **P<0.05, significantly dif-
ferent from control 48 h. C, control or untreated; B2A, 10 µg/ml β2 agonist; 
B2A+SQ, 20 µg/ml AC inhibitor + 10 µg/ml β2 agonist; 8CPT, 20 µg/ml 
Epac activator.
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This study yielded several new findings. To the best of our 
knowledge, we demonstrated, for the first time, that selective 
β2-AR and its related cAMP-Epac signaling pathway stimu-
lation led to the increase of Cx43 expression in astrocytoma 
cells. Secondly, the β2-adrenoceptor-cAMP-Epac signaling 
pathway positively regulates miR-451 expression. Thirdly, 
overexpression of miR-451 had no effect on Cx43 expression. 
These findings not only increase our knowledge of certain 
aspects of the molecular biology of astrocytoma cells, but also 
may provide new potential therapeutic and drug targets. There 
are certain fundamental implications of our findings. In astro-
cytoma and glioma, Cx43 and miR-451 were downregulated. 
Upregulation of them may aid the treatment of astrocytoma and 
glioma, due to their specific effects since the effects of Cx43, 
including decreasing cell proliferation (4) and the bystander 
effect (26) have been proven in previous studies. MiR-451 
overexpression by gene delivery or pharmacological interven-
tion may be used with chemotherapy due to its effect in the 
enhancement of tumor cell sensitivity to chemotherapy agents.
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